Vaping's New Code: Tech Firm Asks FDA to Regulate Software as Tobacco

LOS ANGELES, CA – April 09, 2026 – In a move that could fundamentally reshape the regulation of electronic cigarettes, an AI-focused technology firm has made a novel proposal to the U.S. Food and Drug Administration: treat our compliance software as a tobacco product.

During a formal listening session on Tuesday, IKE Tech LLC, a joint venture including e-cigarette manufacturer Ispire Technology, presented its case to the FDA's Center for Tobacco Products (CTP). The company argued that to effectively combat underage vaping and the flood of illicit devices, the regulatory battleground must shift from the store counter to the device itself, a domain governed by code. This proposition challenges the FDA to expand its definition of a "tobacco product" into the digital realm, a frontier the agency is only just beginning to navigate.

A New Regulatory Paradigm

At the heart of IKE Tech's argument is the assertion that today's enforcement challenges—namely, youth access and counterfeit products—cannot be solved by traditional point-of-sale checks alone. The company is advocating for a shift to "point-of-use" enforcement, powered by a suite of technologies built directly into vaping devices.

"What this engagement with CTP made clear is that today's primary enforcement challenges – underage access and illicit products – cannot be solved at the point of sale alone," said Steven Pryzbyla, a board member of IKE Tech, in a statement. "Point-of-use technologies and software-driven systems have become essential to effective compliance. As a result, the regulatory framework needs to catch up and evolve alongside it."

The company contends that the current Premarket Tobacco Product Application (PMTA) process, designed for evaluating static physical hardware and e-liquids, is ill-suited for the dynamic nature of software. Unlike a fixed chemical formula, software requires continuous updates, security patches, and lifecycle management. By classifying compliance software as a regulated component, IKE Tech hopes to create a formal pathway for its approval and integration. While novel for the CTP, the proposal is not without precedent within the broader FDA, which already oversees software as a medical device. The Tobacco Control Act also grants the agency broad authority to deem new items as "tobacco products," providing a potential legal avenue for such a classification.

Technology at the Point of Use

The software in question is part of a comprehensive compliance platform IKE Tech has developed. The system integrates three key technologies: biometric age-gating that requires user authentication to activate a device, blockchain-based product tracking to verify authenticity and combat counterfeits, and an AI-powered backend for governance and monitoring.

This push for technological solutions aligns with recent signals from the FDA. In March 2026, the agency issued draft guidance on flavored vaping products that, for the first time, formally acknowledged Device Access Restrictions (DAR) as a potentially significant factor in determining if a product is "appropriate for the protection of public health." This guidance suggests that features like biometric locks or geofencing could be used as mitigating measures to prevent youth access.

However, the guidance also sets a high bar. It indicates that DAR technology alone is unlikely to be sufficient to win approval for products with flavors deemed highly appealing to youth, such as candy or fruit. The FDA is taking a "risk-proportionate" approach, where the evidentiary burden on manufacturers increases with the youth-appeal of the flavor. Skeptics, like analysts at the Cato Institute, have suggested this approach risks stifling innovation by setting an impossibly high standard, effectively "foreclosing innovation" in favor of outright restriction.

To bolster its case, IKE Tech points to a multi-center Human Factors Validation Study submitted with its PMTA. The study, published in April 2025, reportedly demonstrated 100% effectiveness in preventing underage users from activating a device, while 91% of adult participants found the system easy to use.

The Business of Compliance

While framed around public health, IKE Tech's strategy is also a calculated business maneuver. By pioneering a regulatory pathway for compliance software, the company and its partners aim to create and dominate a new market segment within the embattled vaping industry.

"We believe the future of compliance must be built directly into the product experience," stated Michael Wang, co-CEO of Ispire Technology.

The venture has already achieved a key milestone. In June 2025, the FDA accepted what IKE Tech describes as the "first standalone component PMTA of its kind" for its interoperable, blockchain-based age-gating technology. This acceptance, following a pre-PMTA meeting in late 2024, signaled the FDA's willingness to review such components separately from a finished tobacco product, potentially streamlining the path to market for compliance technologies.

The commercial potential has not gone unnoticed. Charlie's Holdings, a prominent vape company, has already signed a licensing agreement to commercialize IKE Tech's system, viewing it as a "significant competitive advantage" that could help unlock FDA authorization for flavored products. For Ispire, the potential upside is enormous, with executives suggesting the FDA's new stance on DAR could open up a multi-billion dollar market for compliant flavored devices—a market currently dominated by illicit products.

A Crowded Field and Lingering Questions

IKE Tech is a prominent but not solitary player in the race to solve vaping's compliance puzzle. A growing ecosystem of technology providers is emerging. Companies like VCQRU offer blockchain and AI solutions focused on supply chain integrity and anti-counterfeiting, while age-assurance specialists like Yoti are also active in the market. The concept itself builds on older industry-led track-and-trace systems, though these have faced criticism from public health bodies like the WHO for their lack of independence.

The push for device-level data collection also raises new questions. While promising for enforcement, the integration of biometric data and usage tracking into vaping devices has prompted concerns from privacy advocates about the potential for surveillance and the collection of sensitive personal information.

The dialogue between IKE Tech and the FDA represents a critical juncture for the industry. It pits a technologically sophisticated solution against deep-seated regulatory caution and public health concerns. As regulators, manufacturers, and public health advocates weigh the promise of innovation against the risks, the outcome of this debate will likely define the next chapter of tobacco control in the digital age.